Keryx Biopharmaceuticals Inc. announced it will be transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison. Mr. Bentsur has led Keryx for the past 5 years, culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia (ferric citrate). Mr. Madison joined Keryx in February 2014 as Chief Operating Officer to transition the company from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the phosphate binder and iron deficiency anemia markets.

Mr. Madison has been appointed President of Keryx and will work with Mr. Bentsur to ensure a successful leadership transition by the end of May, when Mr. Bentsur's contract expires. Prior to joining Keryx, Mr. Madison served as the Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals where he led the team to significant growth in net revenues.